164 related articles for article (PubMed ID: 37324547)
21. Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.
Vikse EL; Fossum E; Erdal MS; Hungnes O; Bragstad K
Influenza Other Respir Viruses; 2023 Jun; 17(6):e13144. PubMed ID: 37273461
[TBL] [Abstract][Full Text] [Related]
22. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.
Pochtovyi AA; Kustova DD; Siniavin AE; Dolzhikova IV; Shidlovskaya EV; Shpakova OG; Vasilchenko LA; Glavatskaya AA; Kuznetsova NA; Iliukhina AA; Shelkov AY; Grinkevich OM; Komarov AG; Logunov DY; Gushchin VA; Gintsburg AL
Vaccines (Basel); 2023 Sep; 11(10):. PubMed ID: 37896937
[TBL] [Abstract][Full Text] [Related]
24. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
25. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants.
Singh J; Anantharaj A; Kumar P; Pandey R; Pandey AK; Medigeshi GR
J Interferon Cytokine Res; 2024 Apr; ():. PubMed ID: 38557204
[TBL] [Abstract][Full Text] [Related]
26. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
Bruel T; Vrignaud LL; Porrot F; Staropoli I; Planas D; Guivel-Benhassine F; Puech J; Prot M; Munier S; Henry-Bolland W; Soulié C; Zafilaza K; Lusivika-Nzinga C; Meledge ML; Dorival C; Molino D; Péré H; Yordanov Y; Simon-Lorière E; Veyer D; Carrat F; Schwartz O; Marcelin AG; Martin-Blondel G;
medRxiv; 2023 May; ():. PubMed ID: 37398037
[TBL] [Abstract][Full Text] [Related]
27. The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms.
Buck AM; Deitchman AN; Takahashi S; Lu S; Goldberg SA; Hoh R; Williams MC; Kerbleski M; Deveau TM; Munter SE; Lombardo J; Wrin T; Petropoulos CJ; Durstenfeld MS; Hsue PY; Kelly JD; Greenhouse B; Martin JN; Deeks SG; Peluso MJ; Henrich TJ
medRxiv; 2023 Mar; ():. PubMed ID: 37034660
[TBL] [Abstract][Full Text] [Related]
28. Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies.
Schulz SR; Hoffmann M; Roth E; Pracht K; Burnett DL; Mazigi O; Schuh W; Manger B; Mielenz D; Goodnow CC; Christ D; Pöhlmann S; Jäck HM
Eur J Immunol; 2022 Jun; 52(6):970-977. PubMed ID: 35253229
[TBL] [Abstract][Full Text] [Related]
29. In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library.
González-González E; Carballo-Uicab G; Salinas-Trujano J; Cortés-Paniagua MI; Vázquez-Leyva S; Vallejo-Castillo L; Mendoza-Salazar I; Gómez-Castellano K; Pérez-Tapia SM; Almagro JC
Antibodies (Basel); 2022 Sep; 11(3):. PubMed ID: 36134953
[TBL] [Abstract][Full Text] [Related]
30. Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking.
Liu L; Casner RG; Guo Y; Wang Q; Iketani S; Chan JF; Yu J; Dadonaite B; Nair MS; Mohri H; Reddem ER; Yuan S; Poon VK; Chan CC; Yuen KY; Sheng Z; Huang Y; Bloom JD; Shapiro L; Ho DD
bioRxiv; 2023 Apr; ():. PubMed ID: 37090592
[TBL] [Abstract][Full Text] [Related]
31. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi AS; Bloom JD; Chu HY; Lee KK; Overbaugh J
bioRxiv; 2023 Mar; ():. PubMed ID: 36561191
[TBL] [Abstract][Full Text] [Related]
32. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
33. Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients.
Moal V; Valade M; Boschi C; Robert T; Orain N; Bancod A; Edouard S; Colson P; La Scola B
Front Microbiol; 2023; 14():1147455. PubMed ID: 37065151
[TBL] [Abstract][Full Text] [Related]
34. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants.
Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
medRxiv; 2022 Jan; ():. PubMed ID: 35043120
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
Addetia A; Piccoli L; Case JB; Park YJ; Beltramello M; Guarino B; Dang H; Pinto D; Scheaffer S; Sprouse K; Bassi J; Silacci-Fregni C; Muoio F; Dini M; Vincenzetti L; Acosta R; Johnson D; Subramanian S; Saliba C; Giurdanella M; Lombardo G; Leoni G; Culap K; McAlister C; Rajesh A; Dellota E; Zhou J; Farhat N; Bohan D; Noack J; Lempp FA; Cameroni E; Whitener B; Giannini O; Ceschi A; Ferrari P; Franzetti-Pellanda A; Biggiogero M; Garzoni C; Zappi S; Bernasconi L; Kim MJ; Schnell G; Czudnochowski N; Franko N; Logue JK; Yoshiyama C; Stewart C; Chu H; Schmid MA; Purcell LA; Snell G; Lanzavecchia A; Diamond M; Corti D; Veesler D
bioRxiv; 2023 Feb; ():. PubMed ID: 36711984
[TBL] [Abstract][Full Text] [Related]
36. Fortuitous somatic mutations during antibody evolution endow broad neutralization against SARS-CoV-2 Omicron variants.
Wu J; Chen Z; Gao Y; Wang Z; Wang J; Chiang BY; Zhou Y; Han Y; Zhan W; Xie M; Jiang W; Zhang X; Hao A; Xia A; He J; Xue S; Mayer CT; Wu F; Wang B; Zhang L; Sun L; Wang Q
Cell Rep; 2023 May; 42(5):112503. PubMed ID: 37178120
[TBL] [Abstract][Full Text] [Related]
37. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
38. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J
Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747
[TBL] [Abstract][Full Text] [Related]
39. Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients.
Brandolini M; Gatti G; Grumiro L; Zannoli S; Arfilli V; Cricca M; Dirani G; Denicolò A; Marino MM; Manera M; Mancini A; Taddei F; Semprini S; Sambri V
Microorganisms; 2023 Jan; 11(1):. PubMed ID: 36677483
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
